"The global drug market maintains attractive growth rates and in 2016 is expected to reach the value of 1,200 billion dollars, but growth will mainly be supported by emerging markets, specialty pharmaceuticals and the generics segment. Big Pharma will have to continue to adapt in an increasingly complex ecosystem". Sergio Liberatore, managing director of ImsHealth, summed up the scenario of the challenge that pharmaceutical companies will have to face, on the occasion of the meeting 'Innovating to grow - Challenges and opportunities for the health system with respect to changes in the social scenario' in Tirrenia. We can already see some examples, adds Liberatore: "The ranking of the top 10 companies on the market – he underlines – has remained substantially stable, but the search for balance for the 'top ten' is increasingly complex: in 2004 they absorbed 51% from the market, in 2012 they dropped to 47%".
March 25, 2013 – PharmaKronos
